{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:51:31Z","timestamp":1781635891674,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Scientific Research Fund of the Health Commission of Jilin Province","award":["2022LC019"],"award-info":[{"award-number":["2022LC019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The long noncoding RNA (lncRNA) FAM83H-AS1 plays a critical role in the development and progression of various cancers. This study evaluates the feasibility of serum FAM83H-AS1 as a diagnostic and staging marker for ovarian cancer (OC), addressing its previously unclear diagnostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study included 118 patients diagnosed with OC, 73 individuals with benign ovarian disease (BOD), and 61 healthy controls (HCs). The expression of serum FAM83H-AS1 was quantified via RNA extraction followed by RT-qPCR. The levels of CA125 and HE4 were detected via a chemiluminescence microparticle immunoassay, and the risk of ovarian malignancy algorithm (ROMA) was calculated. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic effect of FAM83H-AS1. Univariate and multivariate Cox regression analyses were employed to identify independent prognostic factors, while Kaplan\u2013Meier analysis with the log-rank test was used to compare survival differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The levels of FAM83H-AS1 were significantly elevated in OC patients compared with those in individuals with BOD and HCs (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Additionally, FAM83H-AS1 expression levels were markedly higher in advanced TNM stages and in cases of metastasis. ROC curve analysis demonstrated robust diagnostic performance for FAM83H-AS1 alone (AUC\u2009=\u20090.824), and the combined FAM83H-AS1\u2009+\u2009ROMA panel achieved superior accuracy (AUC\u2009=\u20090.909). Stepwise multivariate analysis identified FAM83H-AS1 as an independent diagnostic predictor for OC. A unit increase in this marker was associated with a 6.9% increase in the odds of OC (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.030). FAM83H-AS1 levels were positively correlated with TNM stage, lymphatic metastasis, distal metastasis, peritoneal metastasis, and established biomarkers (CA125, HE4, and ROMA;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Notably, postoperative FAM83H-AS1 levels were significantly lower in 22 paired patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), confirming its tumor-derived origin. Survival analysis indicated that elevated serum levels of FAM83H-AS1 expression serve as an independent prognostic factor associated with decreased progression-free survival (PFS) (HR\u2009=\u20098.251,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.041). However, it failed to exhibit independent prognostic significance for overall survival (OS), as the correlation with OS observed in the univariate analysis was rendered non-significant in the multivariate analysis after adjusting for TNM stage. Kaplan-Meier curves further validated significantly worse survival outcomes for patients categorized in the high-expression group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This research is the first to indicate that serum FAM83H-AS1 may serve as a novel noninvasive biomarker for the diagnosis of OC. The combination of FAM83H-AS1 and ROMA demonstrated excellent diagnostic efficacy. Serum FAM83H-AS1 is promising for monitoring the stage and progression of OC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-026-01995-1","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T02:45:42Z","timestamp":1770086742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum long noncoding RNA FAM83H-AS1 serves as a potential noninvasive diagnostic biomarker for ovarian cancer"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9433-2174","authenticated-orcid":false,"given":"Chunying","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshuai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-7206","authenticated-orcid":false,"given":"Xiuyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"3","key":"1995_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1995_CR2","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1995_CR3","doi-asserted-by":"publisher","first-page":"175883592412332","DOI":"10.1177\/17588359241233225","volume":"16","author":"A Ghose","year":"2024","unstructured":"Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli SVN, Erekkath J, et al. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Ther Adv Med Oncol. 2024;16:17588359241233225.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"1995_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian Cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191\u2013226.","journal-title":"J Natl Compr Canc Netw"},{"key":"1995_CR5","doi-asserted-by":"crossref","unstructured":"Stephens AN, Hobbs SJ, Kang SW, Bilandzic M, Rainczuk A, Oehler MK, et al. A novel predictive Multi-Marker test for the Pre-Surgical identification of ovarian cancer. Cancers (Basel). 2023;15(21):5267.","DOI":"10.3390\/cancers15215267"},{"issue":"5","key":"1995_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41580-023-00694-9","volume":"25","author":"J Ferrer","year":"2024","unstructured":"Ferrer J, Dimitrova N. Transcription regulation by long non-coding rnas: mechanisms and disease relevance. Nat Rev Mol Cell Biol. 2024;25(5):396\u2013415.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"1995_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","volume":"24","author":"JS Mattick","year":"2023","unstructured":"Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, et al. Long non-coding rnas: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430\u201347.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1995_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2018.01.053","volume":"419","author":"DH Bach","year":"2018","unstructured":"Bach DH, Lee SK. Long noncoding RNAs in cancer cells. Cancer Lett. 2018;419:152\u201366.","journal-title":"Cancer Lett"},{"issue":"1","key":"1995_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13048-020-00756-y","volume":"14","author":"X Yuan","year":"2021","unstructured":"Yuan X, Huang Y, Guo M, Hu X, Li P. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer. J Ovarian Res. 2021;14(1):6.","journal-title":"J Ovarian Res"},{"key":"1995_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12935-020-1148-8","volume":"20","author":"Q Yang","year":"2020","unstructured":"Yang Q, Wang J, Zhong P, Mou T, Hua H, Liu P, et al. The clinical prognostic value of LncRNA FAM83H-AS1 in cancer patients: a meta-analysis. Cancer Cell Int. 2020;20:72.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1995_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s43046-019-0005-0","volume":"31","author":"DM El-Guindy","year":"2019","unstructured":"El-Guindy DM, Wasfy RE, Abdel Ghafar MT, Ali DA, Elkady AM. Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival. J Egypt Natl Canc Inst. 2019;31(1):3.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"4","key":"1995_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ijc.32277","volume":"146","author":"J Wang","year":"2020","unstructured":"Wang J, Zhang X, Chen W, Hu X, Li J, Liu C. Regulatory roles of long noncoding RNAs implicated in cancer hallmarks. Int J Cancer. 2020;146(4):906\u201316.","journal-title":"Int J Cancer"},{"issue":"1","key":"1995_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-017-0734-4","volume":"16","author":"X Huo","year":"2017","unstructured":"Huo X, Han S, Wu G, Latchoumanin O, Zhou G, Hebbard L, et al. Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells. Mol Cancer. 2017;16(1):165.","journal-title":"Mol Cancer"},{"key":"1995_CR14","doi-asserted-by":"publisher","first-page":"760514","DOI":"10.3389\/fgene.2022.760514","volume":"13","author":"D Qian","year":"2022","unstructured":"Qian D, Qian C, Ye B, Xu M, Wu D, Li J, et al. Development and validation of a novel Stemness-Index-Related long noncoding RNA signature for breast cancer based on weighted gene Co-Expression network analysis. Front Genet. 2022;13:760514.","journal-title":"Front Genet"},{"issue":"2","key":"1995_CR15","doi-asserted-by":"publisher","first-page":"189058","DOI":"10.1016\/j.bbcan.2023.189058","volume":"1879","author":"A Wang","year":"2024","unstructured":"Wang A, Wang Y, Du C, Yang H, Wang Z, Jin C, et al. Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment. Biochim Biophys Acta Rev Cancer. 2024;1879(2):189058.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"Pt 1","key":"1995_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.semcancer.2018.01.012","volume":"52","author":"DA Chistiakov","year":"2018","unstructured":"Chistiakov DA, Myasoedova VA, Grechko AV, Melnichenko AA, Orekhov AN. New biomarkers for diagnosis and prognosis of localized prostate cancer. Semin Cancer Biol. 2018;52(Pt 1):9\u201316.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"1995_CR17","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1002\/jcb.27758","volume":"120","author":"H Shan","year":"2019","unstructured":"Shan H, Yang Y, Zhu X, Han X, Zhang P, Zhang X. FAM83H-AS1 is associated with clinical progression and modulates cell proliferation, migration, and invasion in bladder cancer. J Cell Biochem. 2019;120(3):4687\u201393.","journal-title":"J Cell Biochem"},{"issue":"11","key":"1995_CR18","doi-asserted-by":"publisher","first-page":"8896","DOI":"10.1002\/jcp.26813","volume":"233","author":"YY Bi","year":"2018","unstructured":"Bi YY, Shen G, Quan Y, Jiang W, Xu F. Long noncoding RNA FAM83H-AS1 exerts an oncogenic role in glioma through epigenetically Silencing CDKN1A (p21). J Cell Physiol. 2018;233(11):8896\u2013907.","journal-title":"J Cell Physiol"},{"key":"1995_CR19","doi-asserted-by":"publisher","first-page":"109342","DOI":"10.1016\/j.biopha.2019.109342","volume":"118","author":"L Yang","year":"2019","unstructured":"Yang L, Cui J, Wang Y, Tan J. FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer. Biomed Pharmacother. 2019;118:109342.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"1995_CR20","first-page":"4656","volume":"23","author":"YB Gong","year":"2019","unstructured":"Gong YB, Zou YF. Clinical significance of LncRNA FAM83H-AS1 in ovarian cancer. Eur Rev Med Pharmacol Sci. 2019;23(11):4656\u201362.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"1995_CR21","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1038\/s41598-019-40094-8","volume":"9","author":"JA Barr","year":"2019","unstructured":"Barr JA, Hayes KE, Brownmiller T, Harold AD, Jagannathan R, Lockman PR, et al. Long non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16 E6 independently of p53 in cervical cancer cells. Sci Rep. 2019;9(1):3662.","journal-title":"Sci Rep"},{"issue":"1","key":"1995_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13046-022-02491-2","volume":"41","author":"M Zhou","year":"2022","unstructured":"Zhou M, Pan S, Qin T, Zhao C, Yin T, Gao Y, et al. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect \u03b2-catenin from degradation. J Exp Clin Cancer Res. 2022;41(1):288.","journal-title":"J Exp Clin Cancer Res"},{"key":"1995_CR23","doi-asserted-by":"publisher","first-page":"109961","DOI":"10.1016\/j.biopha.2020.109961","volume":"125","author":"B Wang","year":"2020","unstructured":"Wang B, Guan G, Zhao D. Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt\/\u03b2-catenin signaling pathway. Biomed Pharmacother. 2020;125:109961.","journal-title":"Biomed Pharmacother"},{"key":"1995_CR24","doi-asserted-by":"publisher","first-page":"118193","DOI":"10.1016\/j.lfs.2020.118193","volume":"259","author":"NE El-Ashmawy","year":"2020","unstructured":"El-Ashmawy NE, Hussien FZ, El-Feky OA, Hamouda SM, Al-Ashmawy GM. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic\/prognostic non-invasive biomarkers for breast cancer. Life Sci. 2020;259:118193.","journal-title":"Life Sci"},{"issue":"1","key":"1995_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpan.2024.11.001","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, Lin A, Luo P. Advancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies. Curr Pharm Anal. 2024;21(1):1\u201319.","journal-title":"Curr Pharm Anal"},{"issue":"1","key":"1995_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cpan.2024.12.001","volume":"21","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhao Y, Zhang L. Emerging trends and hot topics in the application of multi-omics in drug discovery: A bibliometric and visualized study. Curr Pharm Anal. 2024;21(1):20\u201332.","journal-title":"Curr Pharm Anal"},{"issue":"20","key":"1995_CR27","doi-asserted-by":"publisher","first-page":"e70106","DOI":"10.1111\/jcmm.70106","volume":"28","author":"Y Feng","year":"2024","unstructured":"Feng Y, Zhang Z, Yang H, Miao F, Li Y, Zhang M, et al. The LncRNA TPTEP1 suppresses PI3K\/AKT signalling and inhibits ovarian cancer progression by interacting with PTBP1. J Cell Mol Med. 2024;28(20):e70106.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1995_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-018-0870-5","volume":"17","author":"H Liang","year":"2018","unstructured":"Liang H, Yu T, Han Y, Jiang H, Wang C, You T, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 2018;17(1):119.","journal-title":"Mol Cancer"},{"issue":"1","key":"1995_CR29","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41467-017-01781-0","volume":"8","author":"R Mitra","year":"2017","unstructured":"Mitra R, Chen X, Greenawalt EJ, Maulik U, Jiang W, Zhao Z, et al. Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun. 2017;8(1):1604.","journal-title":"Nat Commun"},{"issue":"10","key":"1995_CR30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41419-023-06214-z","volume":"14","author":"YB Wu","year":"2023","unstructured":"Wu YB, Li SY, Liu JY, Xue JJ, Xu JF, Chen T, et al. Long non-coding RNA NRSN2-AS1 promotes ovarian cancer progression through targeting PTK2\/\u03b2-catenin pathway. Cell Death Dis. 2023;14(10):696.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1995_CR31","doi-asserted-by":"publisher","first-page":"10505","DOI":"10.1002\/jcb.28336","volume":"120","author":"R Shi","year":"2019","unstructured":"Shi R, Jiao Z, Yu A, Wang T. Long noncoding antisense RNA FAM83A-AS1 promotes lung cancer cell progression by increasing FAM83A. J Cell Biochem. 2019;120(6):10505\u201312.","journal-title":"J Cell Biochem"},{"issue":"18","key":"1995_CR32","first-page":"7855","volume":"23","author":"YK Ma","year":"2019","unstructured":"Ma YK, Shen TH, Yang XY. Upregulation of LncRNA FAM83H-AS1 in hepatocellular carcinoma promotes cell proliferation, migration and invasion by Wnt\/\u03b2-catenin pathway. Eur Rev Med Pharmacol Sci. 2019;23(18):7855\u201362.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"1995_CR33","doi-asserted-by":"publisher","first-page":"152616","DOI":"10.1016\/j.prp.2019.152616","volume":"215","author":"J Da","year":"2019","unstructured":"Da J, Liu P, Wang R, Bu L. Upregulation of the long non-coding RNA FAM83H-AS1 in gastric cancer and its clinical significance. Pathol Res Pract. 2019;215(10):152616.","journal-title":"Pathol Res Pract"},{"key":"1995_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejphar.2019.03.002","volume":"852","author":"Q Dou","year":"2019","unstructured":"Dou Q, Xu Y, Zhu Y, Hu Y, Yan Y, Yan H. LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein. Eur J Pharmacol. 2019;852:134\u201341.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1995_CR35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41416-024-02578-x","volume":"130","author":"C Landolfo","year":"2024","unstructured":"Landolfo C, Ceusters J, Valentin L, Froyman W, Van Gorp T, Heremans R, et al. Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery. Br J Cancer. 2024;130(6):934\u201340.","journal-title":"Br J Cancer"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-01995-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01995-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01995-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:51:53Z","timestamp":1781632313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-01995-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-01995-1","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before the collection of blood samples, all participants signed informed consent forms and were informed about the details of the study. This study strictly adhered to the ethical principles outlined in the Declaration of Helsinki and received approval from the Human Ethics Committee of Jilin Cancer Hospital. Two additional files show this in more detail [see Additional files 1 and 2].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}